Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

•Skeletal-related events (SRE) with tumors have significant patient/economic burden.•Denosumab (RANKL inhibitor) is approved for SRE prevention in MM and solid tumor BM.•Denosumab reduced risk of first/subsequent SREs versus zoledronate in solid tumors.•Denosumab 120 mg every 4 weeks SC is well tolerated, including in renal impairment.•SRE prevention remains important, despite new and effective antitumor therapies.